EEU Coagulation Expert Meeting 2021
Emerging Europe (EEU) Virtual Coagulation Expert Meeting
9 June 2021 | Virtual
CSL Behring has a long tradition in hematology and the treatment of coagulation disorders, during which it also supports education and sharing of information. Therefore, we were honored to participate in the international interactive virtual meeting. We addressed the following topics: current goals and approach to the treatment of Hemophilia A, real-world clinical experience with the use of rFVIII-SingleChain, and key national topics in treatment of Hemophilia A in countries of Emerging Europe.
Video Recordings
Current goals and approach to the treatment of Hemophilia A
Prof. Johannes Oldenburg, MD
Institute of Experimental Haematology and Transfusion Medicine (IHT), University of Bonn, Germany
Duration: 12:23
Survey on current practice in the treatment of Hemophilia A
Prof Cihan Ay, MD
Clinic of Haematology and Haemostaseology, Medical University of Vienna, Austria
Duration: 04:19
Real world experience with rFVIII-SingleChain
Dr Georg Goldmann, MD
Institute of Experimental Haematology and Transfusion Medicine (IHT), University of Bonn, Germany
Duration: 17:15
Experience with rFVIII-SingleChain in pediatric Hemophilia A patients
Dr Martin Olivieri, MD
Pediatric Thrombosis and Hemostasis Unit, Pediatric Hemophilia Centre, Dr. von Hauner Children´s Hospital, LMU Munich, Germany
Duration: 09:44
Initiation and individualization of the treatment with rFVIII-SingleChain
Prof Ingrid Pabinger, MD
Clinic of Haematology and Haemostaseology, Medical University of Vienna, Austria
Duration: 11:12
Treatment PUP patient with rFVIII-SingleChain – case report
Dr Veronika Fiamoli, MD, PhD.
Clinic of Pediatric Hematology, Children’s University Hospital in Brno, Czech Republic
Duration: 06:22
Poland
- AFSTYLA® Summary of product characteristics
- AFSTYLA® Abbreviated Summary of product characteristics
- IDELVION® Summary of product characteristics
- IDELVION® Abbreviated Summary of product characteristics
- Haemate P® Abbreviated Summary of product characteristics
Czech Republic
- AFSTYLA® Summary of product characteristics
- AFSTYLA® Abbreviated Summary of product characteristics
- IDELVION® Summary of product characteristics
- IDELVION® Abbreviated Summary of product characteristics
- Haemate P® Summary of product characteristics
- Haemate P® Abbreviated Summary of product characteristics
Slovakia
- AFSTYLA® Summary of product characteristics
- AFSTYLA® Abbreviated Summary of product characteristics
- IDELVION® Summary of product characteristics
- IDELVION® Abbreviated Summary of product characteristics
- Haemate P® 500 IU Summary of product characteristics
- Haemate P® 500 IU Abbreviated Summary of product characteristics
- Haemate P® 1000 IU Summary of product characteristics
- Haemate P® 1000 IU Abbreviated Summary of product characteristics
Hungary
- AFSTYLA® Summary of product characteristics
- IDELVION® Summary of product characteristics
- Haemate P® Summary of product characteristics
Croatia
- AFSTYLA® Summary of product characteristics
- IDELVION® Summary of product characteristics
- Haemate P® Summary of product characteristics
Slovenia
- AFSTYLA® Summary of product characteristics
- IDELVION® Summary of product characteristics
- Haemate P® Summary of product characteristics
Romania
- AFSTYLA® Summary of product characteristics
- IDELVION® Summary of product characteristics
- Haemate P® Summary of product characteristics
Bulgaria
CMD-AFS-0059
April 2024